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ADAM = a disintegrin and metalloproteinase domain; ADAMTS = ADAM thrombospondin-like repeat; IL = interleukin; Ki = inhibition constant;
MMP = matrix metalloproteinase; NF = nuclear factor; OA = osteoarthritis; RA = rheumatoid arthritis; TIMP = tissue inhibitor of metalloproteinases;
TNFα = tumour necrosis factor alpha.
Arthritis Research and Therapy    Vol 5 No 1 Catterall and Cawston
Introduction
Structural damage to the joint is characteristic of both
rheumatoid arthritis (RA) and osteoarthritis (OA). It is a
predictor of long-term outcome and it contributes over
time to functional decline, disability and major surgical pro-
cedures. Protecting bone and articular cartilage from
damage consequently has major potential both therapeuti-
cally and economically. It has been estimated that approxi-
mately 25% of disability in RA can be explained by
progressive joint damage after the first 5–10 years [1]. If
joint destruction can be prevented or significantly reduced
then the long-term function of joints could be preserved,
severe disability could be avoided and patients would
benefit from a much improved quality of life. The break-
down of cartilage and bone in the arthritides leads to
structural damage and prevents joints from functioning
normally. The present review investigates agents that
protect these tissues and therefore have the potential to
prevent or retard joint damage.
Cartilage contains different types of collagen; these rod-
shaped molecules aggregate in a staggered array, forming
crosslinked fibres that give connective tissues strength and
rigidity [2]. Trapped between the collagen fibres in cartilage
are the proteoglycans [3], molecules that consist of three
globular domains interspersed with heavily glycosylated and
sulphated polypeptide. These form highly charged aggre-
gates that attract water into the tissue, and therefore allow
cartilage to resist compression. Cartilage contains only
chondrocytes, which in normal adult cartilage maintain a
steady state between matrix synthesis and degradation.
In contrast to cartilage, bone contains multiple cell types.
Type I collagen is laid down by osteoblasts and is then
calcified. The resorption of bone requires the formation of
osteoclasts, specialised cells that demineralise bone at
low pH and then degrade collagen. The synthesis of matrix
components during growth and development in both bone
and cartilage exceeds the rate of degradation; a reduction
in matrix synthesis and an increase in the rate of degrada-
tion occurs during matrix resorption.
Extracellular matrix proteins are broken down by different
proteolytic pathways. The four main classes of proteinases
[4] are classified according to the chemical group that
participates in the hydrolysis of peptide bonds. Cysteine
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and aspartate proteinases are predominantly active at acid
pH and act intracellularly; the serine and metallopro-
teinases, active at neutral pH, act extracellularly. Some
enzymes may not participate in the cleavage of matrix pro-
teins, but do activate proenzymes that degrade the matrix.
All classes of proteinase play a part in the turnover of bone
and cartilage; one proteinase pathway may precede
another, and different pathways predominate in various
resorptive situations. The proteinases produced by chon-
drocytes play a major role in OA, while in a rheumatoid
joint proteinases produced by chondrocytes, synovial cells
and inflammatory cells all contribute to matrix loss.
In RA, bone is also destroyed [5]; both the matrix metallo-
proteinases (MMPs) and cysteine proteinases are involved
[6]. When bone is normally resorbed, osteoblasts respond
to agents such as parathyroid hormone, IL-1 and tumour
necrosis factor alpha (TNFα) by increasing the secretion
of MMPs that, once activated, remove the osteoid layer on
the bone surface. Osteoclast precursors then adhere to
the exposed bone surface and differentiate to form a low
pH microenvironment beneath their lower surface that
removes calcium. Lysosomal proteinases are then
released to resorb the exposed matrix. Cathepsin B and
cathepsin L cleave collagen type II, type IX and type XI,
and destroy the crosslinked collagen matrix at low pH [7].
Cathepsin K is also produced by osteoclasts and plays a
key role in the degradation of bone collagen. It cleaves
type I and type II collagen at the N-terminal end of the
triple helix at pH values as high as pH 6.5 [8], and expres-
sion of mRNA for cathepsin K is found at sites of bone
resorption in the rheumatoid joint [9]. When cathepsin K is
deficient, bone resorption is impared. Cathepsin K is also
produced by synovial fibroblasts and is thought to con-
tribute to synovial initiated bone and cartilage destruction
in the rheumatoid joint [10].
Bisphosphonates
History of bisphosphonates
Bisphosphonates were initially used either as corrosion
inhibitors or as complexing agents in the textile, fertilizer or
oil industries [11]. It was shown in the 1960s that
pyrophosphate (Fig. 1) inhibits calcification of tissues by
binding to hydroxapatite but that orally administered
pyrophosphates are hydrolysed in the gut. Bisphospho-
nates are resistant to hydrolysis and so could be adminis-
tered orally [12]. The first bisphosphonate used for human
treatment was etidronate for myositis ossification [13]. It
was discovered that bisphosphonates inhibited osteoclas-
tic-mediated bone resorption [14,15], and this led to their
use as bone protective agents.
Bisphosphonate structure
All bisphosphonates have the same generic structure
(Fig. 1). The hydrolysable oxygen atom that separates the
two phosphate groups in pyrophosphates is replaced with
a more stable carbon atom. The P–C–P structure is
responsible for giving bisphosphonates their high affinity
for bone, which can further be enhanced by the substitu-
tion of a hydroxyl group for the R1 side chain [16]. The R2
side chain is important for conferring the antiresorptive
potency to the bisphosphonates. Extensive modifications
of the R2 side chain showed that a basic primary nitrogen
group attached to an alkyl chain, such as in pamidronate
and alendronate (Fig. 2), produced more potent anti-
resorptive agents (10-fold to 1000-fold) than the earlier
generation bisphosphonates, such as etidronate, with a
single methyl group side chain.
When the nitrogen atom was combined as a tertiary amine
in the R2 side chain, such as in ibandronate and
olpadronate, the bisphosphonates were even more potent.
However, the most potent bisphosphonates to date are
those that contain the nitrogen within a cyclic structure,
such as in risedronate and zoledronate. These cyclic nitro-
gen structures are up to 10,000-fold more active than
etidronate. The structures of the side chains of the bispho-
sphonates used for human therapy are shown in Figure 2
along with their relative potency at inhibiting bone resorp-
tion in rats as compared with etidronate [17].
Mode of action: bone resorption
Bisphosphonates were initially thought to affect bone
resorption by a physical process that directly inhibited the
Figure 1
Structure of pyrophosphate and a generic bisphosphonate.
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dissolution of mineralisation [11]. However, the effective
levels of some newer bisphosphonates to inhibit bone
resorption were well below the levels needed to have a
physical effect. Bisphosphonates predominantly affect
bone resorption by altering the cellular metabolism,
although their ability to bind to the calcified matrix is
important to localise them to bone.
Bisphosphonates target the osteoclast directly either by
increasing apoptosis or by affecting metabolic activity
[11]. The circulating levels of bisphosphonates are
extremely low as they are rapidly absorbed by bone, sug-
gesting that circulating levels are not relevant to function.
This is further supported by the fact that a single large
dose of bisphosphonates can have a sustained effect on
bone resorption [11]. To avoid the potential gastrointesti-
nal problems associated with the newer nitrogen-contain-
ing bisphosphonates, both risedronate and ibandronate
are undergoing clinical trails to determine whether monthly
injection is a suitable delivery method for these bisphos-
phonates [11].
During bone resorption, the osteoclasts demineralise the
extracellular matrix of the bone, and bisphosphonates are
released from the bone surface and absorbed by osteo-
clasts [18,19]. Cellular uptake of bisphosphonates leads
to the loss of the ruffled border between the osteoclast
and the bone surface [20,21], to disruption of the
cytoskeleton [19,22] and to loss of function. Both alen-
dronate and tildronate can inhibit several protein tyrosine
phosphatases [23–25] and can also affect small GTPases
such as Rho and Rac, explaining some of the cytoskeletal
effects. Bisphosphonates also inhibit the osteoclast
proton pumping H+ ATPase [26–28] and lysosomal
enzymes, which contributes to the loss of function.
Bisphosphonates can cause osteoclasts [29],
macrophages [30,31] and myeloma cell lines [32,33] to
undergo apoptosis. The induced osteoclast apoptosis
may be caused by a general disruption that pushes the
cells towards apoptosis, which may account in part for the
inhibition of bone resorption. Bisphosphonates also inhibit
osteoclast differentiation, the formation of osteoclast-like
cells in culture [34] and the generation of mature osteo-
clasts in culture [35–37]; these effects will contribute to
the prevention of bone resorption.
Mode of action: cellular mechanisms
The more potent nitrogen-containing bisphosphonates
inhibit the farnesyl diphosphate synthase enzyme of the
mevalonate pathway [38] that is responsible for producing
cholesterol and isoprenoid lipids. Two of the isoprenoid
lipids, farnesyldiphosphate and geranyldiphosphate, are
required for the normal prenylation of the small GTPases
such as Ras, Rho and Rac; a process essential for the
correct functioning of these enzymes [39] (see Fig. 3).
These small GTPases control the osteoclast cell morphol-
ogy, the cytoskeletal arrangement, membrane ruffling, the
trafficking of vesicles and apoptosis [39–41]. It is believed
that the more potent nitrogen-containing bisphosphonates
inhibit osteoclast function by inhibiting these small
GTPases. This effect on protein prenylation in osteoclasts
has been demonstrated in vivo for aldronate [42].
Bisphosphonates that have a structure similar to
pyrophosphate (e.g. chlodronate and etidronate) become
incorporated into nonhydrolysable analogues of ATP
[43,44], which accumulate within the osteoclast leading to
impaired function. Chlodronate, etidronate and tiludronate
can all be metabolised in mammalian cells [42,45], via the
cytoplasmic aminoacyl-tRNA enzymes. ATP analogues
accumulate within the cytoplasm, where they interfere with
numerous biological processes, eventually causing both
osteoclast and macrophage apoptosis [42]. This appears
Figure 2
Structures of the R1 and R2 side chains (see Fig. 1) of bisphos-
phonates investigated in humans. The bisphosphonates are grouped
according to their potency for inhibiting bone resorption in rats.
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to have been confirmed when the nonhydrolysable ATP
analogue metabolite of chlodronate produced identical
effects to that seen for chlodronate alone [42,46]. Encap-
sulated chlodronate works in an identical manner to cause
apoptosis in macrophages in vivo by a buildup of non-
hydrolysable ATP products in the cytoplasm [42]. The
more potent bisphosphonates that contain a nitrogen in
the side chain are not metabolised in this way [15,25,46].
Mode of action: calcification
Bisphosphonates inhibit calcification by binding to the
surface of solid calcium phosphate crystals and acting as
crystal poisons affecting both crystal growth and dissolu-
tion [47]. There is a positive correlation between the
binding effects of the various bisphosphonates and their
ability to inhibit crystallisation [48], further supporting a
physical mechanism.
Clinical use of bisphosphonates
Bisphosphonates are excellent inhibitors of bone resorp-
tion, with their potency varying according to the structure
of the side chains. Treatment with bisphosphonates
reduces the steady-state level of resorption dependent
upon the administered dose [49,50]. Many different osteo-
porosis models have been investigated [51–56]. Bisphos-
phonates are also effective in decreasing bone loss and
increasing mineral density in postmenopausal osteoporo-
sis [57–62] and corticosteroid-induced bone loss [63].
Bisphosphonates improve the biomechanical properties of
bone in both normal animals and models of osteoporosis
[51,64–67] and, along with hormone replacement
therapy, calcium and vitamin D supplementation, have led
to a significant improvement in the management of osteo-
porosis. It has also been demonstrated that, in humans,
bisphosphonates inhibit tumour-induced bone resorption,
correct hypercalcaemia, reduce pain, prevent the develop-
ment of new osteolytic lesions, prevent fractures and, con-
sequently, improve the quality of life for the patients
[47,68–72].
Rheumatoid arthritis
If bisphosphonates are encapsulated in a liposome, they
are no longer sequestered by the skeleton; instead, they
are taken up by active phagocytic cells such as
macrophages [73]. In animal models, encapsulated clo-
dronate was found to reduce the numbers of
macrophages and to reduce inflammation [74–76]. When
a single intra-articular injection of encapsulated chlo-
dronate was given to patients with RA, a depletion of syn-
ovial macrophages was observed and the treatment was
well tolerated by the patients [77]. Macrophage levels are
predictive of radiological damage in rheumatoid arthritis
[78,79] so that the treatment of patients with encapsu-
lated bisphosphonates could be effective. Certain bispho-
sphonates directly inhibit some MMPs (discussed later).
Inhibition of calcification
In experimental animals, bisphosphonates prevent the cal-
cification of soft tissue [80,81] and are effective in pre-
venting calcification of aortic valve implants [82]. Human
applications have been less successful [83,84] as the
effective dose required to inhibit calcification is enough to
interfere with normal mineralisation. Bisphosphonates
have been shown to be effective at reducing dental calcu-
lus [85,86] when added to toothpaste.
Other effects of bisphosphonates
Many bisphosphonates have an adverse effect upon the
gastrointestinal tract when taken orally, possibly because
they impair cellular metabolism and increase the level of
apoptosis. These side effects are intensified in bisphos-
phonates containing an amine group and include nausea,
dyspepsia, vomiting, gastric pain and diarrhoea. The bis-
phosphonates pamidronate and alendronate, when given
orally, can cause oesophagitis erosions and ulcerations
[87–89]. Some of the nitrogen-containing bisphospho-
nates are potent inhibitors of squalene synthetase, one of
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Figure 3
Schematic showing the mevalonate pathway. Nitrogen-containing
bisphosphonates inhibit the farnesyl diphosphate synthase enzyme,
which prevents the production of farnesyl diphosphate that is required
for protein prenylation. Inhibition of protein prenylation leads to loss of
association of GTP-binding proteins with the cell surface and to a
breakdown in intracellular signalling.
Farnesyl
diphosphate
synthase
Nitrogen
containing
bisphosphonates
Mevalonate
Farnesyl
diphosphate
Geranylgeranyl
diphosphate
Geranylgeranyl
diphosphate
synthase
Rho, Rac,
Rab, Cdc42
Ras Protein
prenylation
Protein
prenylation16
the enzymes in the cholesterol biosynthesis pathway. A
reduction in cholesterol levels after bisphosphonate treat-
ment has been demonstrated in animals [90].
Conclusions
Considerable progress has been made in the design of
new and effective bisphosphonates. The original assump-
tion that the mechanism of action of these compounds
involved a strong physical interaction with the mineral
phase only partially explains their action. It is now recog-
nised that many of the effects result from interfering with
essential cellular functions of osteoclasts. Some actions of
the bisphosphonates can be separated, with different
roles for the backbone and side chains of the molecule. In
the future, it is probable that specific bisphosphonates will
be produced that can target individual metabolic pathways
within the cell to produce more bone-specific actions with
less action on neighbouring cell types, reducing the occur-
rence of side effects.
MMP inhibitors
MMPs are a group of neutral proteinases that collectively
degrade the extracellular matrix. They have a conserved
domain structure and contain a zinc ion at the catalytic
site. The activity of the MMPs is tightly regulated at three
levels: transcriptionally, through transcription factors such
as activator protein 1, NFκB and mitogen-activating
protein kinase pathways; by activation, MMPs are
secreted as inactive zymogen and require the proteolytic
cleavage of the prodomain for activation; and by inhibition,
by the tissue inhibitors of metalloproteinases (TIMPs) that
bind to activated MMPs.
A variety of cytokines increase the production of MMPs,
including IL-1, TNFα, IL-17 and oncostatin M, and these
agents are found within inflamed joints. Some MMPs are
activated intracellularly (membrane-type MMPs and
MMP-11) by furin, a serine proteinase that recognises a
unique motif in the prodomain [91,92]. These enzymes are
thought to initiate activation cascades, and membrane-
type MMPs can activate other MMPs including MMP-13.
MMP-3 and urokinase-type plasminogen activator can also
initiate activation cascades, and both are present in the
joint. Activation is an important control point determining
whether matrix resorption occurs, but the level of active
MMP must exceed those of the TIMPs. There are four
TIMPs that are widely expressed through the body, with all
cell types expressing at least one family member. TIMPs
differ in their ability to inhibit all MMPs. For example,
TIMP-1 cannot inhibit most of the membrane-type MMPs,
and TIMP-4 inhibits MMP-1, MMP-2, MMP-3, MMP-7 and
MMP-9. Tissue destruction thus only occurs when MMPs
are upregulated, are activated and the level of active MMP
exceeds local levels of TIMP (Fig. 4). Any of these three
regulatory steps are potential targets for therapeutic inter-
vention.
A family of metalloproteinases closely related to the MMPs
is also implicated in cartilage biology, particularly in the
turnover of proteoglycan. The family of a disintegrin and
metalloproteinase domain (ADAM) contains proteinases
with diverse functions such as sperm–egg fusion and the
release of cell surface proteins conferred by the addition of
different protein domains [93]. ADAM-17 is known for its
ability to release TNFα from the cell surface [94]. The disin-
tegrin domain, which binds to integrins and prevents cellu-
lar interactions, is found with cysteine-rich, epidermal
growth factor-like, transmembrane and cytoplasmic tail
domains. The ADAM thrombospondin-like repeat
(ADAMTS) family members are distinguished from the
ADAMs in that they lack these latter three domains but
have additional thrombospondin 1 domains at the C-termi-
nus that mediate interactions with the extracellular matrix.
ADAMTS-4 and ADAMTS-5 cleave proteoglycan [95], and
ADAM-10, ADAM-12, ADAM-15 and ADAM-17 are also
found in cartilage. Many members of the ADAMs family are
inhibited by TIMP-3. MMPs are also involved with the
removal of proteoglycan in the later stages of disease.
The cartilage is slowly lost during the arthritic degenera-
tion of a joint, leading to eventual joint failure. The loss of
proteoglycan is a rapid but reversible phenomenon, while
collagen release leads to the loss of the structural integrity
of the collagen and to eventual joint failure. Fibrillar colla-
gen is resistant to proteolytic degradation but at neutral
pH is susceptible to degradation from the collagenases
MMP-1, MMP-8 and MMP-13 that are all found within the
joint. MMP-2 and MMP-14 can also cleave collagen.
Some studies suggest that protecting aggrecan, which is
often released prior to collagen, is the best therapeutic
strategy for joint diseases [96]. Such inhibitors would
need to penetrate the highly charged cartilage matrix prior
to proteoglycan release to be successful. The chondro-
cyte responds to external stimuli by rapidly releasing
aggrecan, possibly as a protective mechanism for tissue
integrity; proteoglycan is resynthesised once the insult is
removed. Inhibition of this response may cause damage in
the longer term. Alternatively, the protection of collagen
means that the inhibitors would prevent damage before it
becomes irreversible.
The two main cell types within the joint, chondrocytes and
synovial lining cells, can make all the known collagenases,
and therefore identifying the major collagenase for a par-
ticular type of arthritis will be important when selecting a
MMP inhibitor. However, the contribution of particular col-
lagenases towards the destruction of arthritic joints
remains to be clearly demonstrated. Both MMP-1 and
MMP-13 have been strongly implicated in the destruction
of cartilage in RA [96–100]. MMP-1 can also be localised
to synovial tissue and is found in high concentrations in
the synovial fluid of rheumatoid patients. While MMP-1
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and MMP-13 are considered the major collagenases,
MMP-2, MMP-8 and MMP-14 may be involved in arthritic
destruction [101,102]. Other enzymes, produced by acti-
vated fibroblasts, may contribute to the overall destruction
of cartilage and bone [103]. There is good evidence that,
in OA, MMP-13 is responsible for much of the collagen
degradation in cartilage as MMP-13-specific synthetic
inhibitors completely block the release of collagen frag-
ments from OA cartilage [104].
Further insights into the biological and pathological role of
MMPs have been gained using transgenic animals and
gene transfer techniques. No rodent MMP-1 could be
detected until recently, but two enzymes (Mcol-A and
Mcol-B) are found within the cluster of MMP genes
located at the A1–A2 position on murine chromosome 9.
These enzymes are most similar to human MMP-1, sharing
74% nucleotide and 58% amino acid homology. One of
these enzymes, Mcol-A, cleaves collagen at the specific
cleavage site and occupies a position sytenic to the
human MMP-1 locus at 11q22. Both enzymes are
expressed during mouse embryogenesis, particularly in
the mouse trophoblast giant cells, although neither
enzyme is as widely distributed as MMP-1 in other species
[105].
This lack of expression of MMP-1 in rodents is a compli-
cating factor making comparisons with human diseases
difficult. Mice deficient in membrane type 1-MMP were
found to have a severe phenotype, with the failure to
turnover collagen at crucial stages of development appar-
ently important [106]. The ability of this enzyme to activate
others such as MMP-13 could be responsible for this
severe phenotype, or nutritional failure at the growth plate
during development could be implicated. Transgenic mice
that overexpress MMP-13 in hyaline cartilage result in ero-
sions that resemble OA lesions with both collagen and
proteoglycan cleavage [107]. Transgenic studies so far
have shown that no MMP/TIMP knockout has been lethal.
It is possible that other MMPs compensate for one
enzyme and this would explain the mild effects seen. For
example, MMP-9 knockout mice had no obvious phento-
typic defects but were shown to exhibit a delay in long
bone growth associated with an abnormal thickened
growth plate, where hypertrophic chondrocytes did not
undergo apoptosis as rapidly as in normal animals [108].
Synthetic MMP inhibitors
The first synthetic MMP inhibitors bound tightly at the
active site and therefore blocked enzyme activity. Effective
inhibitors mimicked the peptide sequences around the
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Figure 4
Control steps for matrix degradation by matrix metalloproteinases (MMPs). Cells are initially stimulated by proinflammatory cytokines through cell
surface receptors. These receptors then transfer the signal to the nucleus via a series of signal transduction pathways leading to mRNA
upregulation. The MMP is synthesised and secreted in an inactive proform and requires activation by enzymic cleavage of the prodomain. Cells also
produce natural inhibitors of MMPs, called tissue inhibitor of metalloproteinases (TIMPs), that inhibit the activated MMPs. Uncontrolled matrix
degradation only occurs when the balance between the TIMP and the active MMP shifts in favour of degradation. MT, membrane type; TNFα,
tumour necrosis factor alpha.
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cleavage site in the substrate, and the scissile bond was
replaced by a chelating group, such as hydroxamate, that
bound to the active site zinc (Fig. 5). Other chelating
groups such as carboxylic acid, thiol and phosphorus have
been used and large numbers of inhibitors have been
made [109]. Early inhibitors (e.g. batimastat, BB-94)
showed broad-spectrum inhibition for many MMPs but
showed poor oral availability. Marimastat (BB-2516;
British Biotech, Oxford, UK), a chemically modified form of
batimastat, shows similar broad-spectrum MMP inhibition
and is also orally active. Initial designs focused on broad-
range inhibitors as it was thought that many MMPs were
involved in cancer. Many inhibitors were produced using
conventional pharmaceutical screening processes before
crystal structures were available, and the detailed chemi-
cal design of MMP inhibitors is reviewed in [109,110].
As the crystal structures of the catalytic domains of MMP-1,
MMP-2, MMP-3, MMP-7, MMP-8, MMP-13, MMP-14 and
MMP-16 became available, new nonpeptide inhibitors with
increased specificity for individual MMPs were made. At
least some of the variation in substrate specificity among
MMPs can be explained by differences in the six specificity
subsites in the active site cleft and surrounding sequences
(Fig. 5). The first subsite on the carboxy-terminal side of the
substrate scissile bond, the S′ pocket, is particularly impor-
tant; for example, it is deeper in MMP-3 and larger in MMP-
8 than it is in MMP-1. This, and differences out to the S′4
position, offer possibilities for designing specificity in syn-
thetic inhibitors. Two examples of nonpeptidyl hydroxamate
inhibitors are prinomastat (AG-3340; Agouron, San Diego,
USA) inhibitor, which is selective for gelatinases over colla-
genases, and Ro32-3555 (Roche, Basel, Switzerland),
which is an effective inhibitor of collagenases but has less
potency against MMP-2 and MMP-3.
MMP inhibitors and arthritis: animal and clinical trials
Many early studies were involved with the treatment of
cancer. For example, marimastat (BB-2516) (an orally
administered hydroxamate inhibitor of MMPs with limited
ability to inhibit sheddase activity) has been in clinical
development since 1994 [111]. A recent study showed
that marimastat significantly improved the survival of
patients with advanced gastric cancer [112].
CellTech (Slough, Berks, UK) developed highly specific
gelatinase inhibitors and proposed that these could be
effective for the treatment of cancer and bone resorption
[113]. Agouron developed prinomastat (AG3340) [114],
a MMP inhibitor with a Ki value in the picomolar range for
the inhibition of MMP-2, MMP-9, MMP-13 and MMP-14,
with lower activity against MMP-1 and MMP-7 [115]. Chi-
roscience (Cambridge, UK) developed D2163, now
licensed to Bristol-Myers Squibb (BMS-275291; New
York, USA), for the potential treatment of cancer. This
compound inhibits a broad range of MMPs associated
with cancer but does not inhibit shedding events, and it
gives a 10-fold increase in systemic exposure for a given
dose when compared with marimastat. BMS-275291
does not exhibit any deleterious side effects with tendons
and joints. The compound prevents angiogenesis in a
mouse model, and phase I studies in healthy volunteers
have been completed showing that good plasma levels
were achieved and that the compound is well tolerated.
BMS-275291 has now entered phase II studies, and the
results will be reported in 2003.
Novartis (formerly Ciba-Geigy; Basel, Switzerland) pub-
lished information regarding an orally active hydroxamate
MMP inhibitor, CGS 27023A. This is a broad-spectrum
inhibitor with a nanomolar Ki against MMP-1, MMP-2,
MMP-3, MMP-9, MMP-12 and MMP-13, and is chon-
droprotective in both the rabbit menisectomy model of OA
and the guinea pig model of spontaneous OA [115].
Another inhibitor, tanomastat (BAY 12-9566; Bayer Corpo-
ration, West Haven, CT, USA), targets MMP-3, MMP-2,
MMP-8, MMP-9 and MMP-13, with low activity against
MMP-1, and was proposed for the treatment of OA. It is
effective in guinea pig and canine models of OA [116], and
human trials of BAY 12-9566 given to 300 OA patients for
3 months reported no musculoskeletal side effects. The
drug was detectable in human cartilage of treated patients
undergoing joint replacement [117]. However, BAY 12-
9566 was withdrawn from an 1800-patient phase III trial in
OA following negative results in a separate cancer trial of
the same drug [115] (see Safety of MMP inhibitors).
Trocade (Ro 32-3555; Roche, Welwyn Garden City, UK), a
selective collagenase inhibitor, was used in phase III trials
for the treatment of RA. It has a low nanomolar Ki against
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Figure 5
Matrix metalloproteinase (MMP) inhibitor interactions. Subsites around
the catalytic zinc (Zn) bind amino acids in the substrate on either side
of the cleavage site. Synthetic MMP inhibitors use a zinc binding group
(ZnBG) attached to modified peptides that can bind tightly to these
subsites. LHS, left-hand side; P, position of residues in the peptide;
RHS, right-hand side; S, subsites of the active site.
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MMP-1, MMP-8 and MMP-13, with approximately 10-fold to
100-fold lower potency against MMP-2, MMP-3 and MMP-
9. It blocks IL-1-induced collagen release from cartilage
explants and, in vivo, has prevented cartilage degradation in
a rat granuloma model, in a Propionibacterium acnes-
induced rat arthritis model and in an OA model using the
SRT/ORT mouse [117]. Clear evidence of protection to
bone and cartilage was apparent even where active inflam-
mation was present. Trocade had no effect on acute inflam-
mation in rodent models, so presumably did not inhibit
TNFα converting enzyme at these concentrations [118].
Large-scale trials of trocade in RA patients, however, were
terminated because of a lack of efficacy. Future data will
show whether adequate concentration of this compound
within the joint was achieved and whether the dosing
schedule used was appropriate. This was the first large-
scale trial in RA, and its failure to complete does leave the
future of therapies targeted at the collagenases in jeop-
ardy [119]. The clinical evaluation of these drugs is diffi-
cult as long trials have to be conducted with radiographs
being the most reliable measure of joint damage. While
some progress has been made with the use of magnetic
resonance imaging, this technology is not yet been proven
and routine centres do not have access to a validated
method for quantitation.
Tetracyclins
Several studies have shown that the antibiotic tetracycline
and its derivatives inhibit MMPs. Micromolar concentra-
tions of tetracycline are sufficient to inhibit collagenase
activity by 50%; greater activity is seen with some modi-
fied tetracyclins [120]. Doxycycline hyclate (Periostat®;
CollaGenex Pharmaceuticals, Newtown, PA, USA), at a
subantimicrobial dose, is the only MMP inhibitor approved
by the US Food and Drug Administration as an adjunct
therapy in adult periodontitis [120]. The results of patient
studies for the use of tetracyclins to treat patients with
rheumatic disease are equivocal [121], although there
were positive trends. There is evidence that, in combina-
tion with nonsteroidal anti-inflammatory drugs, these com-
pounds can be effective, and further studies are planned
with the more potent derivatives [120]. One advantage of
the tetracyclins, if they prove to be effective, is that they
are already in clinical use with a known side-effect profile.
Bisphosphonates as MMP inhibitors
Bisphosphonates may directly inhibit the activity of several
MMPs as tiludronate inhibited MMP-1 and MMP-3 but did
not affect MMP production in periodontal ligament cells
[122]. Chlodronate was able to inhibit MMP-8 in peri-
implant sulcus fluid [123].
Safety of MMP inhibitors
When any new class of drugs is used for the first time it
will raise issues concerning safety. MMPs are involved in a
large variety of physiological processes so the rate of
wound healing, growth and foetal development could all
be affected. There is a balance between matrix synthesis
and matrix breakdown in connective tissues, so inhibition
of MMPs could cause deposition of a matrix, leading to
fibrosis, although dose ranging studies should avoid such
complications.
The most advanced safety data available is for marimastat,
where musculoskeletal pain and tendonitis are identified
as reversible side effects in treated patients [124]. These
effects commence in the small joints of the hand and
spread to the arms, shoulders and other joints if the treat-
ment is continued. The symptoms are time and dose
dependent and could be reversible. These symptoms are
also seen with the Roche compound Ro 31-9790, and
this led to its development as an arthritis treatment being
stopped. Some suggest that these side effects are
caused by inhibition of MMP-1, but the effect is repro-
ducible in rodents, which only express MMP-1 during
embryogenesis [105], and no such events were noted
with trocade, which inhibits MMP-1 very effectively. It is
probable that inhibition of an uncharacterised sheddase
enzyme, similar to TNFα converting enzyme, contributes
possibly via effects on inflammation. All new compounds
can be very effectively screened in rodent models for
these musculoskeletal events and those which cause side
effects discarded.
The Bayer compound BAY 12-9566 was withdrawn as it
was associated with increased tumour growth and poor
survival times in small cell lung cancer, but no other cases
of these effects have been reported [125]. It is not logical
to assume that an effect seen with one member of this
class of compounds will automatically be seen by all and
that there are significant differences in chemical structure
and metabolism of individual inhibitors.
Conclusions about the future of MMP inhibitors
Inhibition of cartilage collagen destruction still remains a
viable target to prevent joint destruction in arthritic
disease. However, the trials of MMP inhibitors have been
extremely disappointing. New agents are still under devel-
opment and these may overcome some of the problems of
both delivery and side effects. A key to future success is
to identify the specific MMPs that are responsible for
arthritic tissue destruction in the different diseases. This
will allow highly specific inhibitors that target individual
enzymes and potentially reduce side effects. It should be
possible to screen all new inhibitors across the MMP
family to ensure specificity. A variety of explanations have
been offered to explain why the metalloproteinase
inhibitors have been unsuccessful in clinical trials in
patients with joint diseases. In addition to a wealth of in
vitro and animal in vivo data, much of the evidence sup-
porting their role in human disease has shown that they
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are ‘at the scene of the crime’. There is no doubt that
MMPs are present and active in joint diseases. However, it
could be that the MMPs or collagenases, in spite of their
presence within the joint, are the wrong target in the arthri-
tides, and that other enzyme systems such as cathepsin K
predominate [126,127].
If MMPs are responsible for cartilage damage, however,
then it is possible that some compounds may not pene-
trate the cartilage/bone synovial interface and are there-
fore ineffective. Compounds may be altered in body
compartments so that their specificity for individual MMPs
is altered. An unrecognised MMP may be the major player
in collagen turnover but is not inhibited by the available
inhibitors, which were screened against a limited set of
available MMPs. Altering the balance between active
MMPs and TIMPs with an artificial inhibitor may upregulate
the synthesis of more MMP and so promote destruction. It
could be that activation is the major control point, and inhi-
bition of the enzyme systems responsible for activation is
the key to success. Alternatively, MMPs are involved in
many cellular functions and the side-effect profiles of com-
pounds that would prevent joint destruction have meant
that effective compounds are excluded during develop-
ment.
Other approaches to MMP inhibition
Although synthetic inhibitors of MMPs have so far proved
to be ineffective, there are several alternative approaches
that can be considered. Much research is being directed
towards the role of cytokines and signalling pathways in
the regulation of the MMPs in disease. Blocking of certain
cytokines or inhibiting the inflammatory cell signalling path-
ways may produce an alternative approach to inhibiting
MMP production and activity. AntiTNFα therapy has
proved successful for treating RA patients, and the levels
of MMPs are reduced. Gene therapy approaches in which
chondroprotective cytokines are overexpressed in affected
joints show that the overexpression of IL-4 and IL-13 in
experimental models of arthritis prevents MMP-induced
cartilage destruction. It may also be possible to increase
the expression of the TIMPs. For example, calcium pen-
tosan polysulphate stimulates the production of TIMP-3 in
human synovial fibroblasts and rheumatoid synovium
without affecting MMP production [128].
As more detailed information about the structure of MMPs
and their interaction with substrates becomes available, it
may be possible to design inhibitors that target areas of
the enzyme other than the active site. For example, the C-
terminal haemopexin-like domain of collagenases has long
been known to be required for collagenolysis, presumably
because of interactions with the substrate [129]. The acti-
vation of the proenzyme is also a valid target, again requir-
ing a detailed knowledge of the underlying biology. An
understanding of the regulation of expression of both
MMPs and TIMPs at the molecular level may allow us to
modulate the levels of both enzymes and inhibitors
expressed by cells during disease. This will require
detailed analysis of the signalling pathways involved in
transforming a cytokine signal at the cell surface to induce
the expression of proteinase or inhibitor. Considerable
effort is being expended in preventing the production of
MMPs by interfering with the cytokine signalling pathways
[130]. Finally, there is interest in the synthesis of modified
TIMPs that are specifically targeted to inhibit specific
enzymes [131–133].
It is interesting that, when patients are treated with the
new anticytokine therapies, a greater protection of the
joint is obtained when this is combined with more conven-
tional treatments. It is probable that blocking of MMPs will
be more effective if combined with treatments that target
earlier steps in inflammation. Furthermore, as noted earlier,
MMPs are not alone in being implicated in joint disease.
Serine proteinases are believed to be involved in MMP
activation, and cysteine proteinases have been shown to
degrade collagen. It may be necessary to combine pro-
teinase inhibitors, either in sequence or with other agents
that hit other specific steps in the pathogenesis, before
the chronic cycle of joint destruction found in these dis-
eases can be broken.
Conclusions
The destruction of bone and cartilage during arthritic and
osteoporotic disease is becoming a major concern with
the ever increasing age of the population. With the
increased prevalence of these diseases, the development
of new therapies and approaches to treatment are
required. Bisphosphonates have proven to be particularly
effective at preventing loss of bone mineral density. They
may also have beneficial effects for treating RA because
encapsulated bisphosphonates are capable of reducing
macrophage levels, and some appear to act directly as
MMP inhibitors.
MMP inhibitors are being developed to directly address
the destruction of cartilage during arthritic disease. The
results from MMP inhibitors in human trials are so far dis-
appointing because these inhibitors suffer from a range of
side effects and show little effectiveness in preventing
joint destruction. The side effects could be overcome with
the use of more specific MMP inhibitors, although this
requires the identification of the enzymes responsible for
arthritic joint destruction. MMP inhibitors may also prove
to be more effective when used in combination therapies,
such as with the biological anticytokine therapies, so that
both the activity and the production of MMPs are reduced.
The development of new therapies coupled to a greater
understanding of the disease processes will lead to the
development of even more effective treatments in the
future.
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